ME02443B - Derivati 1,2,4-tiazolidin-3-ona i njihova upotreba u liječenju kancera - Google Patents
Derivati 1,2,4-tiazolidin-3-ona i njihova upotreba u liječenju kanceraInfo
- Publication number
- ME02443B ME02443B MEP-2016-66A MEP6616A ME02443B ME 02443 B ME02443 B ME 02443B ME P6616 A MEP6616 A ME P6616A ME 02443 B ME02443 B ME 02443B
- Authority
- ME
- Montenegro
- Prior art keywords
- methyl
- thiadiazol
- oxo
- thiadiazolidin
- formula
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 16
- 201000011510 cancer Diseases 0.000 title claims 12
- 150000001875 compounds Chemical class 0.000 claims 37
- 150000003839 salts Chemical class 0.000 claims 28
- 239000012453 solvate Substances 0.000 claims 28
- 125000003118 aryl group Chemical group 0.000 claims 18
- 125000005843 halogen group Chemical group 0.000 claims 17
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 7
- 239000000047 product Substances 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 239000003085 diluting agent Substances 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- -1 -R7 Chemical group 0.000 claims 4
- 238000006243 chemical reaction Methods 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- CTESJDQKVOEUOY-UHFFFAOYSA-N 4-hydroxy-3-[4-(2-hydroxyphenyl)phenyl]-6-oxo-7H-thieno[2,3-b]pyridine-5-carbonitrile Chemical compound OC1=CC=CC=C1C1=CC=C(C=2C=3C(O)=C(C#N)C(=O)NC=3SC=2)C=C1 CTESJDQKVOEUOY-UHFFFAOYSA-N 0.000 claims 2
- NOTGFIUVDGNKRI-UUOKFMHZSA-N AICA ribonucleotide Chemical compound NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 NOTGFIUVDGNKRI-UUOKFMHZSA-N 0.000 claims 2
- BUZAJRPLUGXRAB-UHFFFAOYSA-N AM-251 Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(I)C=C1 BUZAJRPLUGXRAB-UHFFFAOYSA-N 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000007363 ring formation reaction Methods 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 claims 1
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 claims 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 claims 1
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 claims 1
- QPEXDGNCMPBSAR-UHFFFAOYSA-N 2,4-dichloro-n-[2-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(F)=CC=C1CN1C(=O)N=C(NC(=O)C=2C(=CC(Cl)=CC=2)Cl)S1 QPEXDGNCMPBSAR-UHFFFAOYSA-N 0.000 claims 1
- FUXNPGYQRLEJOH-UHFFFAOYSA-N 2,6-dichloro-n-[2-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(F)=CC=C1CN1C(=O)N=C(NC(=O)C=2C(=CC=CC=2Cl)Cl)S1 FUXNPGYQRLEJOH-UHFFFAOYSA-N 0.000 claims 1
- LKOHEZNWJKGELG-UHFFFAOYSA-N 2-(2-phenylethyl)-5-[4-(trifluoromethoxy)anilino]-1,2,4-thiadiazol-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(S1)=NC(=O)N1CCC1=CC=CC=C1 LKOHEZNWJKGELG-UHFFFAOYSA-N 0.000 claims 1
- HGTKLMBPGLDIFR-UHFFFAOYSA-N 2-(2-phenylethyl)-5-[4-(trifluoromethyl)anilino]-1,2,4-thiadiazol-3-one Chemical compound C1=CC(C(F)(F)F)=CC=C1NC(S1)=NC(=O)N1CCC1=CC=CC=C1 HGTKLMBPGLDIFR-UHFFFAOYSA-N 0.000 claims 1
- GWIUBVYZRHTBHY-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-oxo-2-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-thiadiazol-5-yl]acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC(S1)=NC(=O)N1CC1=CC=CC(C(F)(F)F)=C1 GWIUBVYZRHTBHY-UHFFFAOYSA-N 0.000 claims 1
- HNGKUGUJMPSSGY-UHFFFAOYSA-N 2-[(3,4-difluorophenyl)methyl]-5-[4-(trifluoromethoxy)anilino]-1,2,4-thiadiazol-3-one Chemical compound C1=C(F)C(F)=CC=C1CN1C(=O)N=C(NC=2C=CC(OC(F)(F)F)=CC=2)S1 HNGKUGUJMPSSGY-UHFFFAOYSA-N 0.000 claims 1
- XJTWKJIKTOVTGK-UHFFFAOYSA-N 2-[(3,4-difluorophenyl)methyl]-5-[4-(trifluoromethyl)anilino]-1,2,4-thiadiazol-3-one Chemical compound C1=C(F)C(F)=CC=C1CN1C(=O)N=C(NC=2C=CC(=CC=2)C(F)(F)F)S1 XJTWKJIKTOVTGK-UHFFFAOYSA-N 0.000 claims 1
- RJZSSMHOEKAAPX-UHFFFAOYSA-N 2-[(3-fluorophenyl)methyl]-5-[4-(trifluoromethoxy)anilino]-1,2,4-thiadiazol-3-one Chemical compound FC1=CC=CC(CN2C(N=C(NC=3C=CC(OC(F)(F)F)=CC=3)S2)=O)=C1 RJZSSMHOEKAAPX-UHFFFAOYSA-N 0.000 claims 1
- LZADXQXNWDOMDY-UHFFFAOYSA-N 2-[(3-fluorophenyl)methyl]-5-[4-(trifluoromethyl)anilino]-1,2,4-thiadiazol-3-one Chemical compound FC1=CC=CC(CN2C(N=C(NC=3C=CC(=CC=3)C(F)(F)F)S2)=O)=C1 LZADXQXNWDOMDY-UHFFFAOYSA-N 0.000 claims 1
- AMUWSZXTELUHFX-UHFFFAOYSA-N 2-[(4-chlorophenyl)methyl]-5-[4-(trifluoromethoxy)anilino]-1,2,4-thiadiazol-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(S1)=NC(=O)N1CC1=CC=C(Cl)C=C1 AMUWSZXTELUHFX-UHFFFAOYSA-N 0.000 claims 1
- ZNNXRHUTYUXTHC-UHFFFAOYSA-N 2-[(4-chlorophenyl)methyl]-5-[4-(trifluoromethyl)anilino]-1,2,4-thiadiazol-3-one Chemical compound C1=CC(C(F)(F)F)=CC=C1NC(S1)=NC(=O)N1CC1=CC=C(Cl)C=C1 ZNNXRHUTYUXTHC-UHFFFAOYSA-N 0.000 claims 1
- RFZWGFCULXKUMF-UHFFFAOYSA-N 2-[(4-methoxyphenyl)methyl]-5-[4-(trifluoromethoxy)anilino]-1,2,4-thiadiazol-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N=C(NC=2C=CC(OC(F)(F)F)=CC=2)S1 RFZWGFCULXKUMF-UHFFFAOYSA-N 0.000 claims 1
- WYBNVXBKQQMPFJ-UHFFFAOYSA-N 2-[(4-methoxyphenyl)methyl]-5-[4-(trifluoromethyl)anilino]-1,2,4-thiadiazol-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N=C(NC=2C=CC(=CC=2)C(F)(F)F)S1 WYBNVXBKQQMPFJ-UHFFFAOYSA-N 0.000 claims 1
- NHYKNGYFZCJBDR-UHFFFAOYSA-N 2-[2-(4-chloro-n-methylanilino)ethyl]-5-(3,4-dichloroanilino)-1,2,4-thiadiazol-3-one Chemical compound C=1C=C(Cl)C=CC=1N(C)CCN(C(N=1)=O)SC=1NC1=CC=C(Cl)C(Cl)=C1 NHYKNGYFZCJBDR-UHFFFAOYSA-N 0.000 claims 1
- UQVPZZXWWFWQNN-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)sulfanylethyl]-5-(3,4-dichloroanilino)-1,2,4-thiadiazol-3-one Chemical compound C1=CC(Cl)=CC=C1SCCN1C(=O)N=C(NC=2C=C(Cl)C(Cl)=CC=2)S1 UQVPZZXWWFWQNN-UHFFFAOYSA-N 0.000 claims 1
- YPPMKZRGLLMSDM-UHFFFAOYSA-N 2-chloro-6-fluoro-n-[2-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(F)=CC=C1CN1C(=O)N=C(NC(=O)C=2C(=CC=CC=2F)Cl)S1 YPPMKZRGLLMSDM-UHFFFAOYSA-N 0.000 claims 1
- FSHRXYMLLSKYGV-UHFFFAOYSA-N 3,4-dichloro-n-[2-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(F)=CC=C1CN1C(=O)N=C(NC(=O)C=2C=C(Cl)C(Cl)=CC=2)S1 FSHRXYMLLSKYGV-UHFFFAOYSA-N 0.000 claims 1
- NDEIURVSGKHEAW-UHFFFAOYSA-N 3,4-dichloro-n-[2-[1-(4-fluorophenyl)cyclopropyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(F)=CC=C1C1(N2C(N=C(NC(=O)C=3C=C(Cl)C(Cl)=CC=3)S2)=O)CC1 NDEIURVSGKHEAW-UHFFFAOYSA-N 0.000 claims 1
- TZSKWUDSKVQLKM-UHFFFAOYSA-N 3,4-dichloro-n-[4-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-5-ylidene]benzamide Chemical compound C1=CC(F)=CC=C1CN(C(=O)NS1)C1=NC(=O)C1=CC=C(Cl)C(Cl)=C1 TZSKWUDSKVQLKM-UHFFFAOYSA-N 0.000 claims 1
- HWOJETIWOGVVBU-UHFFFAOYSA-N 3,4-difluoro-n-[2-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(F)=CC=C1CN1C(=O)N=C(NC(=O)C=2C=C(F)C(F)=CC=2)S1 HWOJETIWOGVVBU-UHFFFAOYSA-N 0.000 claims 1
- FMPOTICVEOAYQK-UHFFFAOYSA-N 3,5-difluoro-n-[2-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(F)=CC=C1CN1C(=O)N=C(NC(=O)C=2C=C(F)C=C(F)C=2)S1 FMPOTICVEOAYQK-UHFFFAOYSA-N 0.000 claims 1
- UMWQWADVYZQVBY-UHFFFAOYSA-N 3-[[5-(4-chloroanilino)-3-oxo-1,2,4-thiadiazol-2-yl]methyl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(CN2C(N=C(NC=3C=CC(Cl)=CC=3)S2)=O)=C1 UMWQWADVYZQVBY-UHFFFAOYSA-N 0.000 claims 1
- GWQZFXMHKONFOA-UHFFFAOYSA-N 4-[(3,4-difluorophenyl)methyl]-5-[4-(trifluoromethoxy)phenyl]imino-1,2,4-thiadiazolidin-3-one Chemical compound C1=C(F)C(F)=CC=C1CN(C(=O)NS1)C1=NC1=CC=C(OC(F)(F)F)C=C1 GWQZFXMHKONFOA-UHFFFAOYSA-N 0.000 claims 1
- HHEABDHDGHECTF-UHFFFAOYSA-N 4-[(3,4-difluorophenyl)methyl]-5-[4-(trifluoromethyl)phenyl]imino-1,2,4-thiadiazolidin-3-one Chemical compound C1=C(F)C(F)=CC=C1CN(C(=O)NS1)C1=NC1=CC=C(C(F)(F)F)C=C1 HHEABDHDGHECTF-UHFFFAOYSA-N 0.000 claims 1
- DEIHGKFXCGHEGK-UHFFFAOYSA-N 4-[(4-chlorophenyl)methyl]-5-(3,4-dichlorophenyl)imino-1,2,4-thiadiazolidin-3-one Chemical compound C1=CC(Cl)=CC=C1CN(C(=O)NS1)C1=NC1=CC=C(Cl)C(Cl)=C1 DEIHGKFXCGHEGK-UHFFFAOYSA-N 0.000 claims 1
- QGGKZABFKBNKLA-UHFFFAOYSA-N 4-[1-(4-chlorophenyl)cyclopropyl]-5-(4-chlorophenyl)imino-1,2,4-thiadiazolidin-3-one Chemical compound C1=CC(Cl)=CC=C1N=C1N(C2(CC2)C=2C=CC(Cl)=CC=2)C(=O)NS1 QGGKZABFKBNKLA-UHFFFAOYSA-N 0.000 claims 1
- OIWVJMCAPAUNSB-UHFFFAOYSA-N 4-[2-(4-chloro-n-methylanilino)ethyl]-5-(3,4-dichlorophenyl)imino-1,2,4-thiadiazolidin-3-one Chemical compound C=1C=C(Cl)C=CC=1N(C)CCN1C(=O)NSC1=NC1=CC=C(Cl)C(Cl)=C1 OIWVJMCAPAUNSB-UHFFFAOYSA-N 0.000 claims 1
- LVDORRLYOXNORK-UHFFFAOYSA-N 4-[2-(4-chlorophenyl)sulfanylethyl]-5-(3,4-dichlorophenyl)imino-1,2,4-thiadiazolidin-3-one Chemical compound C1=CC(Cl)=CC=C1SCCN(C(=O)NS1)C1=NC1=CC=C(Cl)C(Cl)=C1 LVDORRLYOXNORK-UHFFFAOYSA-N 0.000 claims 1
- OQCAQPYSSFQACS-UHFFFAOYSA-N 4-[[2-[(3,4-difluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]amino]benzonitrile Chemical compound C1=C(F)C(F)=CC=C1CN1C(=O)N=C(NC=2C=CC(=CC=2)C#N)S1 OQCAQPYSSFQACS-UHFFFAOYSA-N 0.000 claims 1
- XKILBXRPFVVUBB-UHFFFAOYSA-N 4-[[4-[(3,4-difluorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-5-ylidene]amino]benzonitrile Chemical compound C1=C(F)C(F)=CC=C1CN(C(=O)NS1)C1=NC1=CC=C(C#N)C=C1 XKILBXRPFVVUBB-UHFFFAOYSA-N 0.000 claims 1
- PAUSNTTWLQLOJH-UHFFFAOYSA-N 4-benzyl-5-(2,4,6-trinitrophenyl)imino-1,2,4-thiadiazolidin-3-one Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=C1N(CC=2C=CC=CC=2)C(=O)NS1 PAUSNTTWLQLOJH-UHFFFAOYSA-N 0.000 claims 1
- KVQYNKBQULGFLP-UHFFFAOYSA-N 4-chloro-n-[2-[(3,4-difluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=C(F)C(F)=CC=C1CN1C(=O)N=C(NC(=O)C=2C=CC(Cl)=CC=2)S1 KVQYNKBQULGFLP-UHFFFAOYSA-N 0.000 claims 1
- WEDWLYRQKUTOAX-UHFFFAOYSA-N 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1CN1C(=O)N=C(NC(=O)C=2C=CC(Cl)=CC=2)S1 WEDWLYRQKUTOAX-UHFFFAOYSA-N 0.000 claims 1
- WWKBAXKETBKLRJ-UHFFFAOYSA-N 4-chloro-n-[2-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(F)=CC=C1CN1C(=O)N=C(NC(=O)C=2C=CC(Cl)=CC=2)S1 WWKBAXKETBKLRJ-UHFFFAOYSA-N 0.000 claims 1
- DTBBLXRBTAHIMV-UHFFFAOYSA-N 4-chloro-n-[2-[2-(4-chloro-n-methylanilino)ethyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C=1C=C(Cl)C=CC=1N(C)CCN(C(N=1)=O)SC=1NC(=O)C1=CC=C(Cl)C=C1 DTBBLXRBTAHIMV-UHFFFAOYSA-N 0.000 claims 1
- ZUHLQVQSIGNCJR-UHFFFAOYSA-N 4-chloro-n-[2-[2-(4-chlorophenyl)sulfanylethyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1SCCN1C(=O)N=C(NC(=O)C=2C=CC(Cl)=CC=2)S1 ZUHLQVQSIGNCJR-UHFFFAOYSA-N 0.000 claims 1
- JUJLKGDZODTHLE-UHFFFAOYSA-N 4-chloro-n-[3-oxo-2-(2-phenoxyethyl)-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C(=O)NC(S1)=NC(=O)N1CCOC1=CC=CC=C1 JUJLKGDZODTHLE-UHFFFAOYSA-N 0.000 claims 1
- VFZXNINYXOCKCV-UHFFFAOYSA-N 4-chloro-n-[3-oxo-4-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-thiadiazolidin-5-ylidene]benzamide Chemical compound FC(F)(F)C1=CC=CC(CN2C(SNC2=O)=NC(=O)C=2C=CC(Cl)=CC=2)=C1 VFZXNINYXOCKCV-UHFFFAOYSA-N 0.000 claims 1
- DYDVLDVRIPKMEL-UHFFFAOYSA-N 4-chloro-n-[4-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-5-ylidene]benzamide Chemical compound C1=CC(Cl)=CC=C1CN(C(=O)NS1)C1=NC(=O)C1=CC=C(Cl)C=C1 DYDVLDVRIPKMEL-UHFFFAOYSA-N 0.000 claims 1
- BYJQGCOTNVMBEJ-UHFFFAOYSA-N 4-chloro-n-[4-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-5-ylidene]benzamide Chemical compound C1=CC(F)=CC=C1CN(C(=O)NS1)C1=NC(=O)C1=CC=C(Cl)C=C1 BYJQGCOTNVMBEJ-UHFFFAOYSA-N 0.000 claims 1
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 claims 1
- IHAHDANKRDSQDI-UHFFFAOYSA-N 4-fluoro-n-[3-oxo-2-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(F)=CC=C1C(=O)NC(S1)=NC(=O)N1CC1=CC=CC(C(F)(F)F)=C1 IHAHDANKRDSQDI-UHFFFAOYSA-N 0.000 claims 1
- CQPHWPNJPUDZJN-UHFFFAOYSA-N 5-(3,4-dichloroanilino)-2-(2-phenoxyethyl)-1,2,4-thiadiazol-3-one Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(S1)=NC(=O)N1CCOC1=CC=CC=C1 CQPHWPNJPUDZJN-UHFFFAOYSA-N 0.000 claims 1
- HXIOAMUSVHJFJR-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)imino-4-(2-phenoxyethyl)-1,2,4-thiadiazolidin-3-one Chemical compound C1=C(Cl)C(Cl)=CC=C1N=C1N(CCOC=2C=CC=CC=2)C(=O)NS1 HXIOAMUSVHJFJR-UHFFFAOYSA-N 0.000 claims 1
- TVKPJNODZCWEJM-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)imino-4-(2-phenylethyl)-1,2,4-thiadiazolidin-3-one Chemical compound C1=C(Cl)C(Cl)=CC=C1N=C1N(CCC=2C=CC=CC=2)C(=O)NS1 TVKPJNODZCWEJM-UHFFFAOYSA-N 0.000 claims 1
- LYSHPGVDISUMCS-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)imino-4-[(3,4-difluorophenyl)methyl]-1,2,4-thiadiazolidin-3-one Chemical compound C1=C(F)C(F)=CC=C1CN(C(=O)NS1)C1=NC1=CC=C(Cl)C(Cl)=C1 LYSHPGVDISUMCS-UHFFFAOYSA-N 0.000 claims 1
- AJVQFHMIZQIECE-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)imino-4-[(3-fluorophenyl)methyl]-1,2,4-thiadiazolidin-3-one Chemical compound FC1=CC=CC(CN2C(SNC2=O)=NC=2C=C(Cl)C(Cl)=CC=2)=C1 AJVQFHMIZQIECE-UHFFFAOYSA-N 0.000 claims 1
- MQVDUIHSNWIVBM-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)imino-4-[(4-methoxyphenyl)methyl]-1,2,4-thiadiazolidin-3-one Chemical compound C1=CC(OC)=CC=C1CN(C(=O)NS1)C1=NC1=CC=C(Cl)C(Cl)=C1 MQVDUIHSNWIVBM-UHFFFAOYSA-N 0.000 claims 1
- AZQPOQDQXYPOTD-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)imino-4-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-thiadiazolidin-3-one Chemical compound FC(F)(F)C1=CC=CC(CN2C(SNC2=O)=NC=2C=C(Cl)C(Cl)=CC=2)=C1 AZQPOQDQXYPOTD-UHFFFAOYSA-N 0.000 claims 1
- HMDIBJPBXYGKBE-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)imino-4-[[4-(1,2,4-triazol-1-yl)phenyl]methyl]-1,2,4-thiadiazolidin-3-one Chemical compound C1=C(Cl)C(Cl)=CC=C1N=C1N(CC=2C=CC(=CC=2)N2N=CN=C2)C(=O)NS1 HMDIBJPBXYGKBE-UHFFFAOYSA-N 0.000 claims 1
- YHLFAOGONXFOMA-UHFFFAOYSA-N 5-(4-chloroanilino)-2-[1-(4-chlorophenyl)cyclopropyl]-1,2,4-thiadiazol-3-one Chemical compound C1=CC(Cl)=CC=C1NC1=NC(=O)N(C2(CC2)C=2C=CC(Cl)=CC=2)S1 YHLFAOGONXFOMA-UHFFFAOYSA-N 0.000 claims 1
- DUARHOWRVABIDW-UHFFFAOYSA-N 5-(6-chloropyridin-3-yl)imino-4-[(3,4-difluorophenyl)methyl]-1,2,4-thiadiazolidin-3-one Chemical compound C1=C(F)C(F)=CC=C1CN(C(=O)NS1)C1=NC1=CC=C(Cl)N=C1 DUARHOWRVABIDW-UHFFFAOYSA-N 0.000 claims 1
- YEGKCBNUIOQIOQ-UHFFFAOYSA-N 5-[(3,4-dichlorophenyl)methylamino]-2-[(3,4-difluorophenyl)methyl]-1,2,4-thiadiazol-3-one Chemical compound C1=C(F)C(F)=CC=C1CN1C(=O)N=C(NCC=2C=C(Cl)C(Cl)=CC=2)S1 YEGKCBNUIOQIOQ-UHFFFAOYSA-N 0.000 claims 1
- SDNFEWYUYLJMFS-UHFFFAOYSA-N 5-[(4-chlorophenyl)methylimino]-4-[(3,4-difluorophenyl)methyl]-1,2,4-thiadiazolidin-3-one Chemical compound C1=C(F)C(F)=CC=C1CN(C(=O)NS1)C1=NCC1=CC=C(Cl)C=C1 SDNFEWYUYLJMFS-UHFFFAOYSA-N 0.000 claims 1
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 claims 1
- QCCSDJVVSABTKP-UHFFFAOYSA-N 5-[(6-chloropyridin-3-yl)amino]-2-[(3,4-difluorophenyl)methyl]-1,2,4-thiadiazol-3-one Chemical compound C1=C(F)C(F)=CC=C1CN1C(=O)N=C(NC=2C=NC(Cl)=CC=2)S1 QCCSDJVVSABTKP-UHFFFAOYSA-N 0.000 claims 1
- MPLLLQUZNJSVTK-UHFFFAOYSA-N 5-[3-[4-[2-(4-fluorophenyl)ethoxy]phenyl]propyl]furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1CCCC(C=C1)=CC=C1OCCC1=CC=C(F)C=C1 MPLLLQUZNJSVTK-UHFFFAOYSA-N 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- ONFKIPLQQJNDCW-UHFFFAOYSA-O O=C1N=C(NC(C=C2)=CC(Cl)=C2Cl)[S+](CCC2=CC=CC=C2)N1 Chemical compound O=C1N=C(NC(C=C2)=CC(Cl)=C2Cl)[S+](CCC2=CC=CC=C2)N1 ONFKIPLQQJNDCW-UHFFFAOYSA-O 0.000 claims 1
- 229940126033 PPAR agonist Drugs 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 claims 1
- 102000000344 Sirtuin 1 Human genes 0.000 claims 1
- 108010041191 Sirtuin 1 Proteins 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 229940046844 aromatase inhibitors Drugs 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000011132 hemopoiesis Effects 0.000 claims 1
- 229940022353 herceptin Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- WSJCPQGBELBKIE-UHFFFAOYSA-N n-[2-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]-3,5-bis(trifluoromethyl)benzamide Chemical compound C1=CC(F)=CC=C1CN1C(=O)N=C(NC(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)S1 WSJCPQGBELBKIE-UHFFFAOYSA-N 0.000 claims 1
- AGHYVPGSDQFGIP-UHFFFAOYSA-N n-[2-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]-4-(trifluoromethoxy)benzamide Chemical compound C1=CC(F)=CC=C1CN1C(=O)N=C(NC(=O)C=2C=CC(OC(F)(F)F)=CC=2)S1 AGHYVPGSDQFGIP-UHFFFAOYSA-N 0.000 claims 1
- JWCZVGWBEPZJLO-UHFFFAOYSA-N n-[2-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC(S1)=NC(=O)N1CC1=CC=C(F)C=C1 JWCZVGWBEPZJLO-UHFFFAOYSA-N 0.000 claims 1
- WMOWRZATFPXDAS-UHFFFAOYSA-N n-[3-oxo-2-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-thiadiazol-5-yl]benzamide Chemical compound FC(F)(F)C1=CC=CC(CN2C(N=C(NC(=O)C=3C=CC=CC=3)S2)=O)=C1 WMOWRZATFPXDAS-UHFFFAOYSA-N 0.000 claims 1
- KIDIYOSDZIEFKU-UHFFFAOYSA-N n-[4-[(3,4-dichlorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-5-ylidene]-3,4-difluorobenzamide Chemical compound C1=C(F)C(F)=CC=C1C(=O)N=C1N(CC=2C=C(Cl)C(Cl)=CC=2)C(=O)NS1 KIDIYOSDZIEFKU-UHFFFAOYSA-N 0.000 claims 1
- NFCQSPSNHQPUEW-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-5-ylidene]-3,5-bis(trifluoromethyl)benzamide Chemical compound FC1=CC=CC(CN2C(SNC2=O)=NC(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=C1 NFCQSPSNHQPUEW-UHFFFAOYSA-N 0.000 claims 1
- ZIPZCMQFNYAKGX-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-5-ylidene]-4-(trifluoromethyl)benzamide Chemical compound FC1=CC=CC(CN2C(SNC2=O)=NC(=O)C=2C=CC(=CC=2)C(F)(F)F)=C1 ZIPZCMQFNYAKGX-UHFFFAOYSA-N 0.000 claims 1
- 229930191479 oligomycin Natural products 0.000 claims 1
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21373509P | 2009-07-08 | 2009-07-08 | |
| EP10759940.9A EP2451794B1 (en) | 2009-07-08 | 2010-07-08 | 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer |
| PCT/GB2010/001315 WO2011004162A2 (en) | 2009-07-08 | 2010-07-08 | Compounds useful as medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02443B true ME02443B (me) | 2016-09-20 |
Family
ID=43086401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-66A ME02443B (me) | 2009-07-08 | 2010-07-08 | Derivati 1,2,4-tiazolidin-3-ona i njihova upotreba u liječenju kancera |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9162994B2 (enExample) |
| EP (1) | EP2451794B1 (enExample) |
| JP (1) | JP5982281B2 (enExample) |
| KR (1) | KR101765957B1 (enExample) |
| CN (1) | CN102596923B (enExample) |
| AU (1) | AU2010270030B2 (enExample) |
| BR (1) | BR112012000370B1 (enExample) |
| CA (1) | CA2767291C (enExample) |
| DK (1) | DK2451794T3 (enExample) |
| EA (1) | EA026674B1 (enExample) |
| ES (1) | ES2567753T3 (enExample) |
| HR (1) | HRP20160353T1 (enExample) |
| HU (1) | HUE027263T2 (enExample) |
| IL (1) | IL216723A (enExample) |
| ME (1) | ME02443B (enExample) |
| MX (1) | MX337516B (enExample) |
| NZ (1) | NZ597075A (enExample) |
| PL (1) | PL2451794T3 (enExample) |
| RS (1) | RS54718B1 (enExample) |
| SG (1) | SG177558A1 (enExample) |
| SI (1) | SI2451794T1 (enExample) |
| SM (1) | SMT201600225B (enExample) |
| WO (1) | WO2011004162A2 (enExample) |
| ZA (1) | ZA201108901B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100931145B1 (ko) * | 2008-07-04 | 2009-12-10 | 현대자동차주식회사 | 조정식 킥 다운 스위치의 조작기구 |
| WO2013108026A1 (en) | 2012-01-17 | 2013-07-25 | Baltic Bio Ab | Thiadiazolone derivatives useful in the treatment of diabetes |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| GB201308325D0 (en) * | 2013-05-09 | 2013-06-19 | Immodulon Therapeutics Ltd | Cancer Therapy |
| US10774064B2 (en) | 2016-06-02 | 2020-09-15 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| ES2908801T3 (es) | 2016-06-07 | 2022-05-04 | Jacobio Pharmaceuticals Co Ltd | Nuevos derivados heterocíclicos útiles como inhibidores de SHP2 |
| HRP20220079T1 (hr) | 2017-01-23 | 2022-04-15 | Cadent Therapeutics, Inc. | Modulatori kalijevih kanala |
| DK3601239T3 (da) | 2017-03-23 | 2024-09-30 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| CA3116339A1 (en) | 2018-10-22 | 2020-04-30 | Cadent Therapeutics, Inc. | Crystalline forms of potassium channel modulators |
| WO2020095010A1 (en) | 2018-11-05 | 2020-05-14 | Balticgruppen Bio Ab | Methods of treating diabetes in severe insulin-resistant diabetic subjects |
| CN109879808B (zh) * | 2019-03-05 | 2020-10-16 | 北京工业大学 | 一种含五元唑类杂环基查尔酮类衍生物及制备方法和医药用途 |
| GB201910092D0 (en) | 2019-07-15 | 2019-08-28 | Balticgruppen Bio Ab | New formulations |
| GB201910093D0 (en) | 2019-07-15 | 2019-08-28 | Balticgruppen Bio Ab | New formulations |
| US11691954B2 (en) | 2019-10-18 | 2023-07-04 | Betagenon Ab | Formulations |
| GB201915094D0 (en) * | 2019-10-18 | 2019-12-04 | Balticgruppen Bio Ab | New formulations |
| GB202015585D0 (en) * | 2020-10-01 | 2020-11-18 | Betagenon Bio Ab | New compounds |
| GB202100352D0 (en) | 2021-01-12 | 2021-02-24 | Balticgruppen Bio Ab | New methods |
| GB202112529D0 (en) | 2021-09-02 | 2021-10-20 | Betagenon Bio Ab | New compounds |
| WO2025017193A1 (en) | 2023-07-20 | 2025-01-23 | Betagenon Ab | Methods of treating cardiomyopathy induced by metabolic inflexibility |
| WO2025017194A1 (en) | 2023-07-20 | 2025-01-23 | Betagenon Ab | Methods for regulating blood glucose levels using a dual ampk activator and mitochondrial uncoupler |
| WO2025027205A1 (en) | 2023-08-03 | 2025-02-06 | Betagenon Ab | Treatment of cancer with the pdk inhibitor 4-chloro-n-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide |
| WO2025252672A1 (en) | 2024-06-03 | 2025-12-11 | Betagenon Ab | Use of tryptophan and metabolites thereof as biomarkers for treatment methods |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4093624A (en) | 1977-01-31 | 1978-06-06 | Icn Pharmaceuticals, Inc. | 1,2,4-Thiadiazolidine-3,5-dione |
| CZ296087B6 (cs) | 2000-05-11 | 2006-01-11 | Consejo Superior Investigaciones Cientificas | Farmaceutický prostredek pro lécbu nemoci, na nízse podílí heterocyklické inhibitory glykogensyntázakinázy GSK-3 |
| ES2166328B1 (es) * | 2000-05-11 | 2003-09-16 | Consejo Superior Investigacion | Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos |
| WO2006045581A1 (en) * | 2004-10-21 | 2006-05-04 | Neuropharma, S.A. | The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators |
| EA200800303A1 (ru) | 2005-07-21 | 2008-10-30 | Бетагенон Аб | Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами |
| WO2008090356A1 (en) * | 2007-01-25 | 2008-07-31 | Betagenon Ab | Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity |
-
2010
- 2010-07-08 ES ES10759940.9T patent/ES2567753T3/es active Active
- 2010-07-08 KR KR1020117030830A patent/KR101765957B1/ko active Active
- 2010-07-08 RS RS20160255A patent/RS54718B1/sr unknown
- 2010-07-08 PL PL10759940T patent/PL2451794T3/pl unknown
- 2010-07-08 NZ NZ597075A patent/NZ597075A/xx unknown
- 2010-07-08 US US13/381,426 patent/US9162994B2/en active Active
- 2010-07-08 EA EA201200102A patent/EA026674B1/ru not_active IP Right Cessation
- 2010-07-08 WO PCT/GB2010/001315 patent/WO2011004162A2/en not_active Ceased
- 2010-07-08 BR BR112012000370-4A patent/BR112012000370B1/pt active IP Right Grant
- 2010-07-08 CN CN201080030894.9A patent/CN102596923B/zh active Active
- 2010-07-08 SI SI201031157A patent/SI2451794T1/sl unknown
- 2010-07-08 MX MX2012000441A patent/MX337516B/es active IP Right Grant
- 2010-07-08 HR HRP20160353TT patent/HRP20160353T1/hr unknown
- 2010-07-08 CA CA2767291A patent/CA2767291C/en active Active
- 2010-07-08 EP EP10759940.9A patent/EP2451794B1/en active Active
- 2010-07-08 DK DK10759940.9T patent/DK2451794T3/en active
- 2010-07-08 JP JP2012519055A patent/JP5982281B2/ja active Active
- 2010-07-08 SG SG2012001236A patent/SG177558A1/en unknown
- 2010-07-08 ME MEP-2016-66A patent/ME02443B/me unknown
- 2010-07-08 HU HUE10759940A patent/HUE027263T2/en unknown
- 2010-07-08 AU AU2010270030A patent/AU2010270030B2/en active Active
-
2011
- 2011-12-01 IL IL216723A patent/IL216723A/en active IP Right Grant
- 2011-12-05 ZA ZA2011/08901A patent/ZA201108901B/en unknown
-
2015
- 2015-10-14 US US14/883,190 patent/US9675596B2/en active Active
-
2016
- 2016-07-12 SM SM201600225T patent/SMT201600225B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02443B (me) | Derivati 1,2,4-tiazolidin-3-ona i njihova upotreba u liječenju kancera | |
| JP2012532854A5 (enExample) | ||
| JP5180099B2 (ja) | 置換イミダゾール誘導体、組成物ならびにｐｔｐアーゼ阻害剤としての使用方法 | |
| EP0733033B1 (en) | Pharmaceutically active substituted aromatic compounds | |
| SK83594A3 (en) | Imidazole derivatives, method of their preparation, their use for production of pharmaceutical compositions with their contents | |
| US20100311748A1 (en) | Heterocyclic amides useful for the treatment of cancer and psoriasis | |
| HRP20170019T1 (hr) | Novi pirol-inhibitori od reduktaze s-nitrozoglutationa kao terapeutska sredstva | |
| JP2008505900A (ja) | 抗炎症性医薬 | |
| SK174699A3 (en) | Inhibitors of factor xa with a neutral p1 specificity group | |
| CN101535303A (zh) | 适合用于治疗与升高的脂质水平有关的疾病的杂环化合物 | |
| HUT70685A (en) | Herbicidal carbamoyloxy-substituted heterocyclic compounds, process for producing them and compositions containing them | |
| KR20030019386A (ko) | 트리아졸 유도체 | |
| WO2004108686A2 (en) | Benzimidazole compounds having hypoglycemic activity | |
| JP2008540574A5 (enExample) | ||
| CA3055292A1 (en) | Metalloenzyme inhibitor compounds | |
| JP2013542201A (ja) | 広域スペクトルのインフルエンザ抗ウイルス剤としての置換されたヘテロアリール基を有する新規ピペラジン類似体 | |
| HUT76639A (en) | Pyridyl-thio-compounds, process for producing them and their use | |
| JPS61189282A (ja) | 駆虫剤としての５‐（アゾリルオキシフエニルカルバモイル）バルビツル酸誘導体及びその製法並びに該化合物を含有する駆虫用組成物 | |
| WO2003090732A1 (en) | Lxr modulators for the treatment of cardiovascular diseases | |
| JPH1149762A (ja) | チアゾール化合物 | |
| WO2014151367A1 (en) | 1,2,5-substituted benzimidazoles as flap modulators | |
| CN1618796A (zh) | 4，5－二取代－2－（1－取代－1h－吡咯－2－基）－噻唑衍生物 | |
| CN103724338A (zh) | 一类含萘环和吡唑啉结构的噻唑类衍生物及其制法 | |
| HK1170485B (en) | 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer | |
| HK1127342B (en) | Substituted imidazole derivatives and there use as ptpase inhibitors |